[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100399003":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":29,"responsibleParty":50,"collaborators":18,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":18,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Antiplatelet treatment discontinuation","EXPERIMENTAL","At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.",[13],"Other: Antiplatelet treatment discontinuation",[15],{"type":6,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.",[9],null,[20,25],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Josep Rodes-Cabau, MD","CONTACT","4186568711","josep.rodes@criucpq.ulaval.ca",{"name":26,"role":22,"phone":27,"phoneExt":18,"email":28},"Melanie Cote, MSc","14186537270","melanie.cote@criucpq.ulaval.ca",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"IUCPQ","RECRUITING","Québec","Quebec","G1V 4G5","Canada","CA",{"type":39,"coordinates":40},"Point",[41,42],-71.21454,46.81228,{"lat":42,"lon":41},[45,46,48],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},{"name":26,"role":22,"phone":23,"phoneExt":47,"email":24},"Rodes-Cabau",{"name":21,"role":49,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Josep Rodes-Cabau","Principal Investigator","100399003","discontinuation-of-antithrombotic-treatment-following-patent-foramen-ovale-closure-in-young-patients-with-cryptogenic-stroke-100399003",false,"NCT04475510","Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke","Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke. The HALTI Trial","HALTI","Inclusion Criteria:\n\n* Successful transcatheter PFO closure with any approved device\n* Patients ≤60 years diagnosed with a cryptogenic stroke\u002FTIA who have undergone successful transcatheter PFO closure\n\nExclusion Criteria:\n\n-\\>60 year-old\n\n* RoPE score \\\u003C6\n* Residual shunt ≥moderate following PFO closure\n* Atrial fibrillation following PFO closure\n* Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia)\n* Diabetes mellitus\n* Thrombophilia (factor V Leiden, factor II mutation, anticardiolipin antibodies, lupus anticoagulant, anti-b2 glycoprotein-I antibodies, protein C deficiency, protein S deficiency)\n* Recurrent cerebrovascular event (stroke, TIA) within the year following PFO closure\n* Failure to provide signed informed consent\n* Absolute contraindications for an MRI study",true,"ALL","18 Years","60 Years",{"count":67,"type":68},100,"ESTIMATED","INTERVENTIONAL",[71],"NA","To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.",[74,75,76],"Patent Foramen Ovale","Ischemic Stroke","Bleeding Ulcer",[78,75,79,80],"Transcatheter Patent Foramen Ovale (PFO) closure","Bleeding","Young patients","2026-03-23",{"date":83,"type":84},"2026-03-24","ACTUAL",{"date":86,"type":84},"2020-07-08",{"date":88,"type":68},"2032-08-01",{"name":52,"class":6},1]